First author and year of publication | Houdt 2021 [54] | Akahoshi 2014 [56] | Eriksson 2016 [55] |
---|---|---|---|
Study type | Retrospective analysis of two prospectively kept databases | Retrospective analysis of one prospectively kept database | Posthoc analysis of a randomized trial |
Aim of the study | to evaluate local recurrence free survival and disease specific survival of GIST patients with or without pretreatment biopsy | To define diagnostic accuracy and safety of and tumor recurrence after EUS-FNA of gastric GIST | To evaluate if percutaneous tumor biopsy has an impact on RFS and OS in patients with GIST receiving adjuvant imatinib after tumor resection |
Number of patients | 228 | 44 | 389 |
Risk of recurrence (low, intermediate, high) | 86, 43, 80, (19 unknown) | 33, 10, 0 | 0, 0, 389 |
Patients with (neo-) adjuvant imatinib | Neoadjuvant 100 adjuvant 158 | 0 | Adjuvant 389 |
Patients with biopsy | 186 | 44 | 47 |
Biopsy technique | CNB = 166, FNA = 20, Transcutaneous = 70, Endoluminal = 116 | EUS-FNA = 44 | CNB = 33, FNA = 22, CNB and FNA = 8 |
Complications of biopsy | N/A | 0 | N/A |
Number of correct diagnoses from pretreatment biopsies | N/A | 32 | N/A |
Recurrence related to biopsy | 1 | 0 | N/Ab |
Total number of abdominal wall or peritoneal recurrences | 25 | 0 | N/Ab |
Follow-up (months) | Median = 53 | Mean = 35, range = 2–108 | Median = 54a |